Technology ID
TAB-4612

Development of Pneumococcal Vaccines

E-Numbers
E-009-2018-1
Lead Inventor
Farley, Monica
Lead IC
CDC
Co-Inventors
Beall, Bernard
Carvalho, Maria Da Gloria
Pimenta, Fabiana
Whitney, Cynthia
Lessa, Fernanda
Milucky, Jennifer
ICs
CDC
Applications
Vaccines­­­
Therapeutics
Research Materials
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)

This technology includes 8 novel strains of the species Streptococcus mitis, Streptococcus oralis, and Streptococcus infantis for vaccine or probiotic development. The capsular biosynthetic genes from each of these strains are highly related to pneumococcal counterparts encoding 5 capsular serotypes. All 8 of these non-pneumococcal strains were recovered from nasopharyngeal (NP) or oropharyngeal (OP) specimens. To achieve their isolation, OP and NP specimens were screened while employing serotype-specific PCR assays and subsequently isolated the positive strains from these specimens through culturing on blood agar plates.

Commercial Applications
To be used for the development as a vaccine against pneumococcal disease or a probiotic that would enable the microbiome to be more protective against disease.

Competitive Advantages
These 5 serotypes are common causes of pneumococcal infections and it is possible that these commensal pathogens (S. mitis and S. oralis) expressing surface polysaccharides that cross-react with pneumococci could lead to cross-protection against pneumococcal disease.
Licensing Contact:
Motley, Jonathan
jonathan.motley@nih.gov